Inicio | Search

Search

Resultados de la búsqueda

Nimotuzumab-cáncer de páncreas-adultos-Fase IV

... Evaluación de la seguridad y efectividad del CIMAher® (Nimotuzumab) en el tratamiento de pacientes con adenocarcinoma de páncreas ... claves:  Nimotuzumab, cáncer de páncreas localmente avanzado, irresecable, ...

Ensayos Clínicos - CIM - 30/07/2019 - 2:43pm

Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT)

... Title:  Nimotuzumab in NSCLC Scientific title:  ... histology NSCLC, treated with concurrent CT-RT plus Nimotuzumab vs concurrent CT-RT. Acronym of ...

Clinical Trials - CIM - 28/12/2018 - 11:16am

Nimotuzumab en Cancer de Pulmon de Celulas No pequenas (CPCNP) de histología epidermoides en estadios III inoperables, concomitante con Quimi-RadioTerapia (QRT)

... Nimotuzumab en CPCNP Título completo del ... III inoperables, tratados con QT-RT concurrente más Nimotuzumab vs QT-RT concurrente. Siglas ... Nimotuzumab en CPCNP concomitante con QRT ...

Ensayos Clínicos - CIM - 28/12/2018 - 11:15am

Nimotuzumab cold kit for the immunodiagnosis of solid tumors

... Efficacy and safety of cold kit of monoclonal antibody nimotuzumab labeled with 99mTc for the immunodiagnosis of head and neck tumors, ... Group I- MAb Nimotuzumab 3mg (Experimental). Immunoscintigraphy with the ...

Clinical Trials - CIM - 05/10/2018 - 8:50am

Kit frío de Nimotuzumab para el inmunodiagnóstico de tumores solidos

... y seguridad del kit frío del anticuerpo monoclonal nimotuzumab marcado con 99mTc para el inmunodiagnóstico de tumores de cabeza y ... claves:  Nimotuzumab, cabeza y cuello, pulmón, gliomas ...

Ensayos Clínicos - CIM - 05/10/2018 - 8:49am

Oncoxin-Viusid/Adenocarcinoma pancreático/Adultos/Fase II

... F., Reuter D, Edler L., and Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor ... et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with ...

Ensayos Clínicos - CATALYSIS - 01/08/2018 - 9:04am

Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)

... preparation NGcGM3/VSSP and the monoclonal antibody nimotuzumab, in patients with advanced non-small cell lung cancer (NSCLC) ... to 24 months Group B (patients with + EGF-R expression) nimotuzumab AcM (intravenous) : 200 mg, the first 6 doses every 7 days, and the ...

Clinical Trials - CIM - 30/04/2018 - 3:00pm

Inmunoterapia con la combinación de NGcGM3/VSSP y nimotuzumab en pacientes con cáncer avanzado de pulmón de células no pequeñas (CPCNP)

... preparado vacunal NGcGM3/VSSP y el anticuerpo monoclonal nimotuzumab, en pacientes con cáncer avanzado de pulmón de células no ... 24 meses Grupo B (pacientes con expresión + EGF-R): AcM nimotuzumab (intravenoso) : 200 mg, las primeras 6 doses cada 7 días, y el ...

Ensayos Clínicos - CIM - 30/04/2018 - 2:59pm

Nimotuzumab-pancreatic cancer-adults-Phase IV.

... Evaluation of the safety and effectiveness of CIMAher® (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma ... Group I (experimental): 2 year treatment with Nimotuzumab 400 mg once a week (intravenous) until discontinuation criteria, in ...

Clinical Trials - CIM - 30/04/2017 - 4:09pm

Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors

... Use of monoclonal antibody Nimotuzumab and radio-chemotherapy in the treatment of patients with locally ... Experimental group: RadioChemotherapy + Anti-EGFR mAb Nimotuzumab at 200 mg intravenously. The Nimotuzumab will have an induction ...

Clinical Trials - CIM - 17/02/2017 - 4:24pm